ND0612, a formation of levodopa/carbidopa administered continuously by an under-the-skin pump, led to better symptom control for people with advanced Parkinson’s disease in a Phase 3 trial, and the therapy’s efficacy and…

Treatment with prasinezumab — an experimental therapy designed to stop toxic alpha-synuclein protein clumps from spreading through the brain — seems to slow the progression of motor symptoms in people with Parkinson’s…

TreeFrog Therapeutics’ investigational cell therapy restored motor function in a rat model of Parkinson’s disease, according to a recent presentation. The therapy, designed to replace the dopamine-producing nerve cells lost in Parkinson’s,…

The Syn-One test, which uses a skin biopsy to look for atypical clumps of the protein alpha-synuclein, may help both in confirming a diagnosis and guiding treatment decisions for people being evaluated for…

AB-1005, an experimental gene therapy administered directly into the brain, helped ease motor symptoms in patients with moderate Parkinson’s disease, whereas it appeared to stabilize disease progression for those with mild disease…